痴呆症神经退行性疾病中的睡眠障碍:综合性审查
Natalia Siwecka1,2, Michał Golberg3,4, Dominika Świerczewska1
1Department of Neurology, Medical University of Lodz, 22 Kopcinskiego Street, 90-153 Lodz, Poland.
Journal of clinical medicine
|October 16, 2025
概括
睡眠障碍会使痴呆症患者的认知能力下降和心理健康恶化. 解决睡眠问题可以改善生活质量,并减缓神经退行症的进展.
科学领域:
- 神经学和精神病学 精神病学
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
背景情况:
- 痴呆症在全球影响超过5500万,随着人口老龄化而增加.
- 神经退行性疾病 (如阿尔茨海默氏症,帕金森病) 是导致痴呆的主要原因.
- 痴呆症的认知衰退通常伴随着睡眠障碍和心理健康问题.
研究的目的:
- 审查主要神经退行性疾病中的睡眠障碍.
- 为了总结睡眠障碍的治疗策略.
- 讨论痴呆症中睡眠与精神健康相互作用的临床相关性.
主要方法:
- 关于痴呆症,睡眠障碍和心理健康的当前研究的文献评论.
- 分析睡眠障碍与神经精神病症状之间的双向关系.
- 综合发现,以告知临床管理和未来的研究.
主要成果:
- 睡眠障碍 (失眠,REM睡眠行为障碍等) 在神经退行性疾病中普遍存在.
- 在睡眠中断加剧神经精神症状的地方存在反循环,反之亦然.
- 这些相互作用有助于疾病的进展和降低生活质量.
结论:
- 了解痴呆症中睡眠与精神健康的联系对于有效管理至关重要.
- 需要多学科的方法来解决神经退行症的复杂性.
- 针对睡眠障碍提供了改善症状控制和减缓认知衰退的潜力.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.帕金森病是帕金森氏症的一种疾病.昼夜节律 昼夜节律认知能力下降 认知能力下降痴呆症 痴呆症是一种痴呆症.综合护理是一项综合护理.神经退行症的神经退行症神经炎症是一种神经炎症.神经精神病学是一种神经精神病学.睡眠障碍 睡眠障碍 睡眠障碍更多相关视频
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
6.0K
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.2K
相关概念视频
Dementia
515
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
515
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
REM Sleep Behavior Disorder
1.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
1.4K
Narcolepsy
490
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
490
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
